Search
Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept
He reminds us of the unmet need for this type of therapy and discusses the planning that Vera has been doing ahead of the decision date. Coverage brought to you by
Apr 14
SF Healthcare Week: Vera Therapeutics’ announced this week that the FDA accepted the company’s filing for atacicept, a potential new treatment for IgA Nephropathy
Founder and CEO Marshall Fordyce talks about the data that supported the application and describes how atacicept’s novel mechanism holds the potential to transform the treatment of the autoimmune disease. He says the company is getting ready to launch, with a PDUFA date set for July.
Jan 11
Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego
Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR...
Oct 27, 2024
Taking a deep dive into the IgA nephropathy (IgAN) space with the CEO of Vera Therapeutics
Marshall Fordyce describes the rationale of targeting both BAFF and APRIL as a B-cell modulator for IgAN.
Feb 13, 2024
.png){kind=logo}
